Navigation Links
FIRMAGON® Results in Fast, Long-Term Suppression of Testosterone in Prostate Cancer Patients Without Initial Testosterone Surge
Date:6/1/2010

s of transaminases and gamma-glutamyltransferase (GGT). Ninety-nine percent of these observed adverse reactions were Grade 1 or 2 (mild to moderate). Specifically relating to the injection site adverse reactions, most were transient, of mild to moderate intensity, occurred primarily with the starting dose and led to few discontinuations (<1%). Grade 3 (severe) injection site reactions occurred in two percent or less of patients receiving FIRMAGON.  

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company.  Ferring Pharmaceuticals offers a line of infertility, gynecology, urology, and orthopaedic products in the U.S. market.  They include: LYSTEDA™ (tranexamic acid),  BRAVELLE® (urofollitropin for injection, purified), MENOPUR® and REPRONEX® (menotropins for injection, USP), Novarel® (chorionic gonadotropin for injection, USP), ENDOMETRIN® (progesterone) Vaginal Insert, 100 mg, FIRMAGON® (degarelix for injection), PROSED® DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate), DESMOPRESSIN, and EUFLEXXA® (1% sodium hyaluronate).

Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, orthopaedics, gastroenterology, obstetrics/gynecology, and infertility.  

For more information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.

  1. Labrie F. J Androl. 2004;25(3):30
    '/>"/>

SOURCE Ferring Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year
2. Cantel Medical Corp. to Hold Conference Call to Discuss Results for Its Third Quarter Ended April 30, 2010
3. Elbit Imaging Ltd. Announces First Quarter Results for 2010
4. The New England Journal of Medicine Publishes Results of Landmark CREST Study, Showing Similar Positive Outcomes for Abbotts Carotid Stent System and Surgery
5. Abbotts Groundbreaking Bioresorbable Technology Continues to Demonstrate Exceptional Clinical Results
6. Abbotts Investigational MitraClip(R) System Demonstrates Strong Safety Results and Improved Clinical Outcomes for Common Causes of Leaky Heart Valves
7. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
8. China Yongxin Pharmaceuticals Reports First Quarter 2010 Financial Results
9. Bayer HealthCare Pharmaceuticals, Inc. Announces Results of a Phase 3 Clinical Trial of Gadobutrol
10. Concord Medical to Report First Quarter 2010 Financial Results on Thursday, May 27, 2010
11. China Ruitai International Holdings Co., Ltd. Reports Results for the First Quarter 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Research and Markets has announced the addition ... report to their offering. Multiple ... in demyelination, axonal transection, and neurodegeneration. The myelin sheath ... immune system, which targets neurons within the central nervous ... which the damage of the myelin sheath causes disruption ...
(Date:8/29/2014)... Pixcelldata, the innovative Irish developer of digital ... new deal with Dutch based eX-Path, global providers of ... Marius Nap . The announcement was made ... which is taking placing between August 30th and September ... where Pixcelldata will demonstrate its innovative solution. ...
(Date:8/28/2014)... , Aug. 28, 2014  Rigrodsky & Long, P.A.: ... Company, Inc. (NYSE: LCI )? , Did you ... 2013 and July 16, 2014, inclusive? , Did you ... Do you want to discuss your rights? ... United States Attorney, Timothy J. MacFall , announces that a ...
Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3
... 12, 2011 Endo Pharmaceuticals (Nasdaq: ENDP ) ... 27, 2011 and will host a conference call and webcast ...   David P. Holveck, president and CEO of ... vice president of R&D, Alan Levin, executive vice president and ...
... Oct. 12, 2011 Reportlinker.com announces that a ... catalogue: Pen Injectors ... and the availability of an increasing number of ... propelling the growth of injector pens at the ...
Cached Medicine Technology:Endo Pharmaceuticals to Announce Third Quarter 2011 Financial Results on October 27, 2011 2Pen Injectors 2Pen Injectors 3
(Date:8/30/2014)... 2014 In today’s world, a good night’s ... Snoring and sleep apnea (a medical problem where the airway ... bed partners of the rest they need to face their ... snores and 20 million people in the United States alone ... and treated; and of those treated, many cannot tolerate their ...
(Date:8/30/2014)... One of the most recent dietary trends ... diet. Originally meant for sufferers of gluten intolerance and celiac ... who are looking to get healthier by simply consuming foods ... kind of information erroneous, it also exposes those same consumers ... a drastic change in their food consumption habits. ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 The new review ... program was created by Karen Brimeyer, who wanted to make ... , This guide is now easy to find in ... download. In this guide, the author of the new method ... , Daily Gossip writes in its review that the ...
(Date:8/30/2014)... 30, 2014 August 28th, 2014: ... in our society and the toll that takes on ... vital that continuing education for physical therapists addresses this ... physical therapists help others, Hands-On Seminars is offering discounts ... , Three learning styles are available to fit the ...
(Date:8/30/2014)... NJ (PRWEB) August 30, 2014 Ms. Meriwether’s ... her. She certainly has an impressive resume to boost. ... Miss USA in 2012. However, she’s also a two ... Grad student. Nana trained for the 2008 Olympics and ... Miss USA website, “This six-foot beauty from Potomac, Maryland is ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:“What is Gluten: Three Things You Need to Know Before Adopting a Gluten-Free Diet” Reveals What Readers Need to Know About the Benefits of a Strict Gluten Diet - Vinamy 2Health News:Leaky Gut Cure Review Reveals Unique Method to Stop Chronic Symptoms 2Health News:Leader in Manual Therapy Continuing Education Makes it Easier for Physical Therapists to Improve Results on Patients 2Health News:NJ Top Dentists Announces Cover Model for the Healthy Living: Top Dentists Issue 2
... Ind., April 14 Conseco, Inc. (NYSE:,CNO) ... promoted to vice president,enterprise risk management, reporting ... actuary. Mr. Bischof is responsible for overseeing ... conjunction,with Conseco,s Enterprise Risk Management Committee., ...
... April 14 Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ), ... and audio web cast on Wednesday, April 30, 2008,at ... release of its,financial results for the first quarter ended ... 6:30 a.m. ET on Wednesday,April 30, 2008., To ...
... male hormone in the morning made more money , , MONDAY, ... finds that financial traders who wake up with high levels ... that day, probably because they feel more daring. , ... stress hormone cortisol tend to be more cautious. , "We ...
... The Pharmaceutical Care,Management Association (PCMA) issued the ... New York Times on skyrocketing biotech prices:, ... and will,spend $100 billion within a few years. ... because they don,t face generic competition once their,patents ...
... Cogdell Spencer,Inc. (NYSE: CSA ) announced today that ... on Monday, May 5, 2008. Cogdell Spencer,Inc. invites you ... May 6, 2008 at 10:00 a.m. (Eastern Time). The ... or (412) 858-4600,(international). In addition, the conference call can ...
... that hypertension should still be treated , , MONDAY, April ... are less likely to have headaches than those with ... one headache expert cautions that the new research does ... or stop taking their blood pressure medications. , The ...
Cached Medicine News:Health News:Testosterone Levels Among Financial Traders Affect Performance 2Health News:Testosterone Levels Among Financial Traders Affect Performance 3Health News:Cogdell Spencer Inc. Announces First Quarter Earnings Release and Conference Call Notice 2Health News:High Blood Pressure May Be Buffer Against Headaches 2Health News:High Blood Pressure May Be Buffer Against Headaches 3
... The Professional Gold Package ... your laboratory. The package includes ... and automated system, starter package ... v-block adapter, specimen mounts 1/2" ...
... provides a versatile means of sectioning fresh ... The 1000 employs a vibrating blade principle ... The creation of artifacts, the alteration ... and other deleterious effects inherent in freezing ...
... The NEW Vibratome 3000 Plus Sectioning System ... or fixed, animal, or plant tissues. ... which allows sectioning without freezing or embedding. ... of morphology, the destruction of enzyme activities, ...
... 3000 Deluxe Sectioning System provides a versatile ... or plant tissues. The 3000 employs ... without freezing or embedding. The creation ... destruction of enzyme activities, and other deleterious ...
Medicine Products: